Skip to main content

Table 2 Apoptosis and proliferation in cell tumour experiments

From: Effect of a farnesyl transferase inhibitor (R115777) on ductal carcinoma in situ of the breast in a human xenograft model and on breast and ovarian cancer cell growth in vitro and in vivo

Cell line Control Treated R115777
   50 mg/kg 100 mg/kg
MCF-7/HER2-18    
   Ki67 (%) 77.7 (74.4–81.1) 69.6** (63.4–74.8) 65.5**** (62.0–70.1)
   TUNEL (%) 1.2 (0.9–1.5) 1.5* (1.2–1.6) 1.6** (1.4–1.9)
   CTI 61.6 (55.5–79.5). 48.7*** (41.6–57.4) 38.0**** (30.1–43.3)
SKOV3    
   Ki67 (%) 46.6 (32.0–63.8) 34.1** (20.3–57.2) 40.1 (26.6–48.8)
   TUNEL (%) 0.35 (0.1–0.8) 0.49 (0.1–1.0) 0.48 (0.1–1.4)
   CTI 125.4 (87.1–188.9). 67.5**(45.6–96.1) 81.0* (38.6–110.2)
MDA-MB231    
   Ki67 (%) 61.7 (54.1–74.6) 69.3 (56.1–78.0) 72.4* (43.8–83.1)
   TUNEL (%) 0.55 (0.3–0.9) 0.45 (0.3–0.6) 0.31* (0.1–0.4)
   CTI 106.0 (85.8–191.0). 180.1 (115.9–205.4) 180.8 (90.5–227.7)
  1. Effect of R115777 on proliferation (Ki67), apoptosis (TdT-mediated dUTP-fluorescence nick end labelling [TUNEL]) and cell turnover index (CTI) in cell line tumours grown in athymic nude mice. Values are expressed as median values (interquartile range). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
\